Sun Pharma Adv.Res.Co.Ltd Opens Gap-Up at ₹205.87 After M&A Update — Levels, Volumes and the Follow-Up to Track

Sun Pharma Adv.Res.Co.Ltd share price today, and the reason behind it

Shares of Sun Pharma Adv.Res.Co.Ltd are changing hands at ₹203.27 on the NSE board as of 05:05 pm IST on 8 September 2026 — -2.60 or -1.28% from the previous close of ₹203.27. Behind the number, the session opened above the previous close, so the open is the pivot: holding above it keeps the gap intact, losing it signals the early bid is being unwound.

Key takeaways

• Where it trades: Sun Pharma Adv.Res.Co.Ltd is at ₹203.27, -2.60 (-1.28%) versus the previous close of ₹203.27.
• Why it is moving: a m&a story — 2 business desks filed on the company in the last few hours.
• Today's band: ₹201.25 to ₹206.96, against an open of ₹205.87 — the stock has given up its opening print.
• Twelve-month context: 29.66% below the ₹289 high and 88.21% above the ₹108 low, so the stock sits in the middle part of its own range.
• Participation: turnover is running at 0.7x the twenty-day average, which is ordinary flow — the move lacks a volume endorsement so far.
• What to watch: the swap ratio and the regulatory approval calendar, which decide when the structure actually takes effect.

The m&a angle

The reason Sun Pharma Adv.Res.Co.Ltd is on the desks today is a m&a story — run by 2 publishers, with the headlines linked below. A merger or demerger changes the entity being valued, so the price has to reprice against a new set of cash flows and a swap ratio rather than against last quarter's numbers.

Today's quote in numbers

What changes when the entity itself changes

In a merger, demerger or acquisition the market stops valuing the company it was valuing yesterday. Past quarterly numbers describe an entity that will not exist in the same form, so the price has to be rebuilt around a new set of cash flows, a new debt position and — in a share-swap deal — a fixed exchange ratio that ties this stock's value to another's.

The swap ratio is where most of the day-one move comes from: if the ratio implies a value different from the traded price, arbitrage desks trade the gap until the two converge. After that, the calendar takes over. Board approval is only the first step; competition-authority clearance, creditor and shareholder meetings and tribunal approval each carry their own timeline, and deals routinely take several quarters to become effective.

Sun Pharma Adv.Res.Co.Ltd at ₹203.27, -2.60 on the day, is trading the probability of completion as much as the economics of the combination.

Coverage across the desks

Headlines are listed for context and link straight to the publisher. The prices, ranges and tables on this page are read independently from exchange data at the timestamp shown.

• Sun Pharma gets ratings boost from Moody's, S&P over USD 11.75-bn Organon & Co acquisition bid — Economic Times
• Sun Pharma gets ratings boost from Moody's, S&P over ₹11.75-billion Organon & Co acquisition bid — The Hindu BusinessLine

What the tape is saying

Sun Pharma Adv.Res.Co.Ltd has traded between ₹201.25 and ₹206.96 in this session against an open of ₹205.87 and a previous close of ₹203.27. That is a band of ₹5.71, or 2.81% of the current price — an ordinary day's spread, so the move is orderly rather than disorderly.

Trading below the open at ₹205.87 puts everyone who bought the first print underwater, and that cohort is the first source of supply on any bounce — which is why sessions that lose the open rarely close on the high.

In market-structure terms this is a continuation session, so the prior trend remains the base case until a level breaks.

Performance across horizons

What the returns table is saying

Over the last week Sun Pharma Adv.Res.Co.Ltd has slipped -2.14% and over the month -6.32%. Both horizons pointing the same way means the recent move is an extension of the existing trend rather than a reversal.

The twelve-month return of +44.07% is the context long-term holders judge the stock on. A moderate one-year move means the stock has broadly tracked its earnings path rather than being re-rated in either direction.

Reading the price against its own ranges

Over the last twelve months the price has covered ₹108 to ₹289. The current level is 53% of the way through that band, 29.66% below the 52-week high and 88.21% above the 52-week low. A mid-range price means neither the bulls nor the bears own the trend yet; the twelve-month extremes are the levels that decide which way the range resolves.

Traded quantity of 6,27,055 shares is 0.67x the 20-day average of 9,39,684. Turnover close to the recent norm suggests an orderly session rather than a scramble, so the move reflects ordinary two-way flow.

Where this goes from here

For this m&a story specifically, watch the swap ratio and the regulatory approval calendar, which decide when the structure actually takes effect. On the chart, the ₹206.96 high and ₹201.25 low of this session are the reference levels — a higher low in the next session turns a headline reaction into a trend, a break of today's low usually voids it. Participation is the third check: the move needs turnover at or above the stock's own 20-day average of 9,39,684 shares to be read as positioning rather than a squeeze.

Trader's view versus investor's view

For a trader, this is a low-information session: the move sits inside the stock's normal daily spread, so there is no edge in chasing it. Waiting for a close outside ₹201.25–₹206.96 is the cheaper way to be positioned.

For a long-term shareholder, this is an event with an open-ended outcome, and the market is pricing a range rather than a number. The company's own exchange clarification — not the headline — is the document that narrows that range, and it is worth waiting for before adding or trimming.

On risk: this report is a reading of live exchange data at a point in time, and intraday levels change. Position sizing — not conviction about the story — is what determines the outcome of a trade built on a headline, and averaging into a falling price without a change in the underlying facts is how a trade becomes an unintended long-term holding.

Our read

Sun Pharma Adv.Res.Co.Ltd is being sold on a m&a story, and at ₹203.27 the decline is happening on ordinary turnover, which is more often a shakeout than distribution. The day's ₹201.25–₹206.96 band is the frame for the next session, and the swap ratio and the regulatory approval calendar, which decide when the structure actually takes effect is what resolves the story either way.

Where to track SPARC next

Live price, charts and technicals stay on the Sun Pharma Adv.Res.Co.Ltd stock page, and every filed quarter is tabulated on its quarterly results page. Both pages refresh from the exchange feed through the session, so they carry a later reading than this report once the market has moved on.

Frequently asked questions

What is the Sun Pharma Adv.Res.Co.Ltd share price today?

Sun Pharma Adv.Res.Co.Ltd (SPARC) last traded at ₹203.27, -2.60 (-1.28%) against the previous close of ₹203.27, read from the NSE board at 05:05 pm IST on 8 September 2026.

Why is Sun Pharma Adv.Res.Co.Ltd in the news today?

2 business publishers ran headlines on the company in the last session — a m&a story. Their reports are linked above; the levels and tables here are read independently from exchange data.

What is the 52-week high and low of SPARC?

Over the last twelve months SPARC has traded between a low of ₹108 and a high of ₹289, computed from the adjusted daily series.

Is SPARC up or down today?

SPARC slipped -1.28% in this session, trading between ₹201.25 and ₹206.96 against an open of ₹205.87.

Key takeaways

• Last price: ₹203.27 (-1.28%) — lower at the time of writing
• Day range: ₹201.25 – ₹206.96
• 52-week high: ₹289

About this report

Every figure on this page is read from a primary source at the timestamp shown — exchange boards for equities and indices, the exchange bid book for IPOs, published association rates for bullion, and consolidated exchange quotes for crypto — with no estimation or third-party commentary. Historical fields such as trailing returns and 52-week extremes are computed on the adjusted daily series so splits and bonuses do not create false gaps. A timestamp outside market hours reflects the last traded or last published value, not a live tick.

Related live pages

• Sun Pharma Adv.Res.Co.Ltd share price
• Sun Pharma Adv.Res.Co.Ltd quarterly results
• Stocks in news
• Top gainers
• Market dashboard

Sources

• NSE live board data via our exchange data feed
• Headline attribution links above point to the original publishers
• TrendRipperX Sun Pharma Adv.Res.Co.Ltd stock page

“This report is generated automatically from live exchange and official association data at the time stamped above. Prices move continuously — verify on the source before acting. Nothing here is investment advice.”